Greycoat's US Gambit: AIM Science Fuels 8.5x Surge in Feline Health Market

LAS VEGAS, NV – August 05, 2026

Next week, amidst the sprawling booths and industry buzz of SUPERZOO 2026, a South Korean company named Greycoat Research will unveil its “Cat Kidney Store” concept. On the surface, it’s another international brand vying for a piece of the lucrative American pet market. But look closer, and this is no ordinary product launch. This is the culmination of a corporate maneuver that has already seen the company’s U.S. sales explode by an astonishing 8.5-fold in a single year.

Greycoat Research’s arrival in Las Vegas isn’t a cold open; it’s a strategic escalation. The company has quietly validated its product-market fit with staggering success, and its appearance at the industry’s premier event is a signal flare. It telegraphs a major play in the high-stakes, science-driven pet wellness sector, fueled by a compelling founder narrative and a revolutionary approach to one of feline medicine’s most intractable problems: chronic kidney disease (CKD).

Decoding the Market Signal: An 850% Growth Anomaly

In the world of corporate strategy, numbers are the ultimate truth-tellers. Greycoat Research's internal data reveals a story of explosive, almost unprecedented, organic growth. The company recorded an 850% increase in U.S. sales between 2024 and 2025, with that momentum holding strong through the first half of this year. The United States, once a peripheral market, now accounts for 67% of the firm's total international sales. This isn't just growth; it's a market actively pulling a product across borders before a formal distribution strategy is even in place.

This surge is happening against the backdrop of a booming U.S. pet industry, projected to reach $165 billion in 2026. More importantly, the market is shifting. The modern pet owner, particularly among Millennial and Gen Z demographics, acts more like a proactive parent than a passive keeper. They demand sophisticated, evidence-based solutions and are willing to invest heavily in preventative care and specialized treatments. Greycoat’s success indicates it has tapped directly into this powerful consumer current.

“For a foreign company to achieve this level of sales velocity prior to a major channel push is exceptionally rare,” noted one pet industry analyst. “It suggests they’ve solved a significant, unmet need that has sent consumers searching past domestic options. Their challenge at SUPERZOO isn’t to find a market, but to build the infrastructure to service the one that has already found them.”

The launch of the “Cat Kidney Store” concept, featuring supplements and nutritional guidance, is the strategic response to this demand. It’s a move to consolidate their gains, build trusted partnerships with distributors and retailers, and transition from a direct-to-consumer phenomenon into a mainstream contender.

The Science of Longevity: The AIM Protein Revolution

The engine behind Greycoat’s phenomenal growth is not marketing savvy alone, but a deep alignment with groundbreaking scientific research. The company’s products are based on the work of Dr. Toru Miyazaki, a Japanese immunologist who identified a key reason why cats are uniquely susceptible to kidney failure.

Dr. Miyazaki’s research uncovered that the AIM protein (apoptosis inhibitor of macrophage), a crucial component of the body’s waste-disposal system, functions abnormally in cats. In most mammals, AIM detaches from a larger antibody cluster (IgM) to flag cellular debris for removal. In felines, a genetic quirk causes their AIM to bind to IgM with a strength 1,000 times greater than in other species, effectively keeping it inactive. Over a cat’s lifetime, this leads to an accumulation of cellular waste in the kidneys, ultimately causing the organ to fail.

The potential for a therapeutic intervention is profound. A landmark study co-authored by Dr. Miyazaki, published in The Veterinary Journal in February 2026, demonstrated that an injectable, lab-created recombinant AIM (rAIM) dramatically extended the survival of cats with advanced CKD. This research has created a tidal wave of hope among veterinary professionals and cat owners.

Herein lies a critical distinction. The injectable “FeliAIM” is an investigational drug currently undergoing regulatory review in Japan. Greycoat Research, working under the advisory of Dr. Miyazaki, is not selling this drug. Instead, its products—the Greycoat Dr. Toru supplement and AIM Bites treats—are “AIM-based” nutritional solutions designed to support a cat’s natural kidney function within this scientific framework. While the competitive landscape includes established supplements like Porous One and Azodyl, Greycoat’s approach is fundamentally different. It aims to address the underlying biological mechanism identified by Dr. Miyazaki, offering a new paradigm in a field long focused on symptom management.

The Founder's Gambit: From Personal Mission to Market Disruption

If AIM science provides the product’s credibility, the company’s origin story provides its soul. Greycoat Research was born from the personal crisis of its CEO, Claire Yun. Eight years ago, her beloved grey-coated cat, TT, was diagnosed with Stage 2 CKD. Yun, who runs the popular YouTube channel “Claire Luvcat” with 1.3 million subscribers, refused to accept the grim prognosis and dove into the world of feline nephrology.

Her search led her to Dr. Miyazaki’s then-nascent research. Inspired, she founded Greycoat Research—named in TT’s honor—with a singular mission. This narrative of a dedicated owner turning personal desperation into a global enterprise is a powerful market differentiator. It builds a level of trust and authenticity that traditional corporate branding struggles to replicate. TT, whose kidney health has remained stable for eight years under this dedicated care regimen, serves as the brand’s living proof-of-concept.

In her official statement, Claire Yun captures this ethos perfectly. “Our journey began with TT and a simple goal—helping more cats with kidney disease live healthier and happier lives,” she said. “Eight years later, that commitment continues to shape everything we do. SUPERZOO marks our next step in bringing that mission to more cats and building trusted, long-term partnerships across North America.”

Greycoat’s strategy is a masterclass in modern brand building, where a compelling scientific breakthrough is fused with an authentic, relatable human story. The company’s presence at SUPERZOO is therefore more than a sales pitch; it's the formal U.S. debut of a mission-driven enterprise that has already proven its disruptive potential. The challenge now is to translate that potent combination of science and story into enduring market dominance.